

PHARMACEUTICAL 2021



INTEGRATED BIOPHARMA INC Rank 233 of 402







PHARMACEUTICAL 2021



INTEGRATED BIOPHARMA INC Rank 233 of 402

The relative strengths and weaknesses of INTEGRATED BIOPHARMA INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of INTEGRATED BIOPHARMA INC compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 217% points. The greatest weakness of INTEGRATED BIOPHARMA INC is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 220% points.

The company's Economic Capital Ratio, given in the ranking table, is 73%, being 26% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	16,461
Cost of Goods Sold	46,042
Intangible Assets	0
Liabilities, Current	13,099
Liabilities, Non-Current	3,778
Other Assets	4,787
Other Compr. Net Income	0
Other Expenses	-1,020
Other Liabilities	0
Other Net Income	-171
Other Revenues	52,769
Property and Equipment	1,696
Research and Development	0
Selling, General and Administrative Expense	3,468

Output Variable	Value in 1000 USD
Assets	22,944
Liabilities	16,877
Expenses	48,490
Revenues	52,769
Stockholders Equity	6,067
Net Income	4,108
Comprehensive Net Income	4,108
Economic Capital Ratio	73%

